An evaluation of small-molecule p53 activators as chemoprotectants ameliorating adverse effects of anticancer drugs in normal cells

Pharmacological manipulation of the cell cycle and metabolism to protect normal tissues against conventional anticancer drugs

(2015) Ingeborg van Leeuwen et al.   Oncotarget

Activation of p53 by SIRT1 Inhibition Enhances Elimination of CML Leukemia Stem Cells in Combination with Imatinib

(2012) Ling Li et al.   CANCER CELL

A p53-independent role for the MDM2 antagonist Nutlin-3 in DNA damage response initiation

(2011) Jane M Valentine et al.   BMC CANCER

SIRT2 Maintains Genome Integrity and Suppresses Tumorigenesis through Regulating APC/C Activity

(2011) Hyun-Seok Kim et al.   CANCER CELL

Mechanism-specific signatures for small-molecule p53 activators

(2011) Ingeborg M.M. van Leeuwen et al.   CELL CYCLE

Selective killing of cancer cells by a small molecule targeting the stress response to ROS

(2011) Lakshmi Raj et al.   NATURE

The c-MYC oncoprotein, the NAMPT enzyme, the SIRT1-inhibitor DBC1, and the SIRT1 deacetylase form a positive feedback loop

(2011) A. Menssen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

SIRT1 Promotes N-Myc Oncogenesis through a Positive Feedback Loop Involving the Effects of MKP3 and ERK on N-Myc Protein Stability

(2011) Glenn M. Marshall et al.   PLoS Genetics

Protection of p53 wild type cells from taxol by nutlin-3 in the combined lung cancer treatment

(2010) Sergey V Tokalov et al.   BMC CANCER

Cellular quiescence caused by the Mdm2 inhibitor Nutlin-3A

(2010) Lioubov G. Korotchkina et al.   CELL CYCLE

Specific activation of the p53 pathway by low dose actinomycin D: A new route to p53 based cyclotherapy

(2010) Meng Ling Choong et al.   CELL CYCLE

Combination of nutlin-3 and VX-680 selectively targets p53 mutant cells with reversible effects on cells expressing wild-type p53

(2010) C F Cheok et al.   CELL DEATH AND DIFFERENTIATION

The C terminus of p53 binds the N-terminal domain of MDM2

(2010) Masha V Poyurovsky et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

DNA damage response to the Mdm2 inhibitor Nutlin-3

(2009) Rajeev Verma et al.   BIOCHEMICAL PHARMACOLOGY

Identification of Nuclear Export Inhibitors with Potent Anticancer Activity In vivo

(2009) S. C. Mutka et al.   CANCER RESEARCH

Pharmacologic p53 Activation Blocks Cell Cycle Progression but Fails to Induce Senescence in Epithelial Cancer Cells

(2009) B. Huang et al.   MOLECULAR CANCER RESEARCH

A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53

(2009) S. Sur et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Discovery, In Vivo Activity, and Mechanism of Action of a Small-Molecule p53 Activator

(2008) Sonia Lain et al.   CANCER CELL

Impaired DNA Damage Response, Genome Instability, and Tumorigenesis in SIRT1 Mutant Mice

(2008) Rui-Hong Wang et al.   CANCER CELL

Transient Nutlin-3a Treatment Promotes Endoreduplication and the Generation of Therapy-Resistant Tetraploid Cells

(2008) H. Shen et al.   CANCER RESEARCH

Nutlin-3a Activates p53 to Both Down-regulate Inhibitor of Growth 2 and Up-regulate mir-34a, mir-34b, and mir-34c Expression, and Induce Senescence

(2008) K. Kumamoto et al.   CANCER RESEARCH